ClariVest Asset Management’s Minerva Neurosciences NERV Stock Holding History

ClariVest Asset Management’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,650	Closed	-$236K	–	700
2017 Q1	$236K	Buy	3,650 +37	+1%	+$2.87K	0.01%	464
2016 Q4	$339K	Buy	3,613 +288	+9%	+$29.4K	0.01%	440
2016 Q3	$376K	Buy	3,325 +62	+2%	+$6.02K	0.01%	419
2016 Q2	$266K	Buy	+3,263	New	+$207K	0.01%	444

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

ClariVest Asset Management's NERV Position: Q2 2017 in Review

ClariVest Asset Management sold out of Minerva Neurosciences (NERV) in Q2 2017, closing a stake of 3,650 shares — an estimated $236K sold.

ClariVest Asset Management first reported a position in NERV in Q2 2016 and held it in 4 quarters. The position peaked at $376K in Q3 2016. 82 funds tracked by Wall St. Rank hold NERV as of Q2 2017.

ClariVest Asset Management reported no remaining Minerva Neurosciences position as of Q2 2017 after selling out during the quarter.
ClariVest Asset Management sold 3,650 Minerva Neurosciences shares in Q2 2017, an estimated $236K.
ClariVest Asset Management first reported a position in Minerva Neurosciences in Q2 2016 and held it in 4 quarters.
ClariVest Asset Management's Minerva Neurosciences position peaked at $376K in Q3 2016.
82 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2017.

Based on ClariVest Asset Management's 13F filing for Q2 2017, filed 2 Aug 2017.